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Jie Gao2, Cheng Yang3, Jun Han1,2* and Wei Li1,2*Abstract: Nanomedicine offers new hope to overcome the low solubility and high side toxicity to normal tissue
appeared in traditional chemotherapy. The biocompatibility and intracellular drug accumulation is still a big challenge
for the nano-based formulations. Herein, a medical-used biocompatible arabinoxylan (AX) is used to develop to delivery
chemodrug doxorubicin (DOX). The solubility of DOX is obviously enhanced via the hydrogen bond formed with AX
which results in an amphiphilic AX-DOX. A micelle with pH-cleavable bond is thus self-assembled from such AX-DOX
with DOX core and AX shell. The inner DOX can be easily released out at low intracellular pH, which obviously enhanced
its in vitro cytotoxicity against breast cancer cells (MCF-7). Interestingly, an unexpected apoptosis is evoked except for
the proliferation inhibition. Moreover, the therapeutic effects are further synergistically promoted by the enhanced
permeability and retention (EPR) and intracellular pH-triggered drug release. Consequently, the in vivo intratumor
accumulation of DOX, the tumor inhibition was significantly promoted after intravenous administration to the Balb/c
nude mice bearing MCF-7 tumors. These in vitro/vivo results indicated that the AX-DOX micellular formulation holds
high potential in cancer therapy.
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The small molecular chemodrug DOX is widely used in
clinic due to its high cytotoxicity against many tumors,
including liver cancer, lymphoma, gastric cancer, and
breast cancer [1–4]. The clinic merit is strongly limited
by its side effects to the normal tissue which is attrib-
uted to its low aqueous solubility, quick degradation,
and poor in vivo tumor-targeting capability [5]. There-
fore, development of new DOX formulation is highly de-
sired. Nanomedicine offers new hope in overcoming the
abovementioned drawbacks [6, 7] by some advantages
such as in vivo stability [8], controlled drug dosage [9],
and low toxicity [10]. Many nano formulations based on
liposomes [11], nano-gel [12], and polymeric micelles* Correspondence: junhanmail@163.com; liwei@smmu.edu.cn
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the Creative Commons license, and indicate if[13] have been extensively investigated recently. For fur-
ther promoting their therapeutic index, the biocompati-
bility of the carriers and intracellular drug distribution
are still needed to improve [6, 7, 14].
Noted, the AX is a natural polysaccharide and has
been used in the medical field for the advantages of good
biocompatibility and amphiphilicity [15] which is con-
firmed in its clinical trials and used in food [16, 17].
Moreover, AX is a chemosensitizing agent in the treat-
ment of cancer [18]. Additionally, there are many –NH2
and –OH groups along the AX chain backbone, which
deems the AX should be an excellent candidate for
design of novel pH-sensitive nanomedicine with acid-
responsive hydrogen bond [19]. In such case, the solubil-
ity of DOX can be enhanced via the hydrogen bond and
hydrophobic interaction. On the other hand, the stability
of AX-based nanomedicine can be promoted by the
hydrophilic AX. The inner DOX can be easily released
out at relatively low pH [20]. It is well known that theis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Wang et al. Nanoscale Research Letters  (2017) 12:73 Page 2 of 9pH value of the normal cells is ~7.3. However, the pH in
tumor is around 6.2–6.9. In some organelles such as
endosomes and lysosomes, the acidity lowers to 4.5–6.0
[21]. This pH difference between tumor and non tumor
cells offers an opportunity to control the intracellular
drug release because the micelles can stably circulated in
physiological conditions (pH 7.3) and release drug at the
intracellular low pH.
In this study, a AX-DOX micelle was facilely prepared
through hydrogen bond and hydrophobic interactions
[19]. The biocompability of AX and the pH cleavable
AX-DOX bonds were successfully utilized in this case.
The nanoparticle’s properties, in vitro/vivo synergistic
antitumor effects and corresponding mechanism, were
systemically investigated. This study provided an easy
and feasible idea for the design and preparation of pH-
sensitive nano delivery system.
Methods
Materials
The AX was provided by the School of Chemical and Ma-
terial Engineering, Jiangnan University. Doxorubicin
hydrochloride (DOX∙HCl) was purchased from Dalian
Meilun bio Co., Ltd. (Dalian, China). Methanol, acetone,
chloroform, acetonitrile, chloroquine (CQ), and 3-
methyladenine (3-MA) were bought from Sigma (St.
Louis, MO, USA). N,N-dimethylacetamide (DMAC) and
triethanolamine (TEA) were of analytical grade and were
used without further purification. All organic reagents
were of analytical grade and purchased from Sinopharm
(Shanghai, China) unless specifically mentioned otherwise.
For in vitro cell culture, fetal bovine serum (FBS), the
Dulbecco’s modified Eagle’s medium (DMEM) cell cul-
ture media, penicillin, and streptomycin were purchased
from Invitrogen (Carlsbad, CA, USA). The cell counting
kit-8 (CCK-8) was purchased from Dojindo laboratories
(Kumamoto, Japan). An Annexin V-FITC/PI Apoptosis
Detection Kit was purchased from Becton, Dickinson
and Co. (NJ, USA).
Water was purified using a Milli-Q Synthesis A10 sys-
tem (Millipore, Billerica, MA) in terms of resistivity
18.2 MΩ cm.
Synthesis of Micelles
Typical synthesis procedure was outlined as follows:
AX was dissolved in 1 mL DMAC (5 mg/mL). In
order to fully dissolve, the mixture was stirred for
10 min at 120 °C with oil bath heating. The reaction
system was cooled naturally to reach room temperature
before adding the DOX mixture. DOX∙HCl was also dis-
solved in 1 mL DMAC (5 mg/mL). We prepared a TEA
solution with 1.5 M equivalents to the DOX in DMAC
and made tenfold dilution with DMAC. The TEA solution
was added slowly dropwise into the DOX solution andkept stirring for about 5 min. Then, the DOX and the AX
solution were mixed at a drug-to-nanocarrier feeding ratio
of 1:1 and stirred for 24 h in dark at room temperature
(RT). Afterward, the free DOX was removed by dialyzing
against PBS using the dialysis membrane (molecular
weight cutoff (MWCO), 1 kDa) in dark at RT, and this
dialysis was kept for about 24 h with regularly replacing
fresh PBS every 8 h. Finally, the AX-coated DOX (i.e.,
AX-DOX) micelles were collected and stored at 4 °C
for further use.
In this article, the DOX is hydrophobic doxorubicin
unless specifically mentioned otherwise.
Characterization of micelles
The morphology of micelles was characterized using
scanning electron microscopy (SEM) (Hitachi, Tokyo,
Japan). The SEM experiments were conducted by depos-
iting 10 μl of aqueous solutions of the micelles on a sili-
con chip and allowing them to dry for 60 min in air.
Samples were imaged with an SEM. The conventional
SEM images were obtained at 1.0 kV.
The hydrodynamic diameter and size distribution of mi-
celles were studied by dynamic light scattering (DLS, ALV/
CGS-3, Germany) instrument by dispersing the micelles
(1 mg/mL) in Milli-Q water at the scattering angle of 90°.
DOX Encapsulation Efficiency Studies
The encapsulation efficiency (EE) and the drug loading
capacity (DLC) of DOX in the micelles were calculated
by the following equations:
EE ¼ MEncapsulated=MFed  100% ð1Þ
DLC ¼ MEncapsulated=MTotal  100% ð2Þ
where MEncapsulated represents the weight of DOX encap-
sulated in the micelles, MFed is the total weight of DOX
fed for encapsulation, and MTotal is the total weight of
micelles including both the encapsulated DOX and the
non-DOX materials for making the empty micelles. The
amount of DOX was dissolved in acetonitrile and vig-
orously vortexed to gain a solution at a drug-to-
nanoparticle feeding ratio of 1:1 and then determined
using UV-Vis spectrophotometer (Cary300, Varian, CA,
USA) based on the absorbance at 485 nm.
DOX Release Studies
The DOX release profiles were detected by a fluores-
cence spectrofluorometer (Cary Eclipse, Varian, CA,
USA) using three different buffers: PBS 7.4, PBS 6.5, and
acetate buffer at pH 4.5, which represent the pH of
blood, the pH of the tumor microenvironment, and the
pH of lysosomes and endosomes [22], respectively. Re-
lease studies from micelles were prepared as the follow-
ing: 1 mL of micelles solution including the same
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(MWCO 3.5 kDa) that were placed in 100 mL of release
buffer at 37 °C for 48 h. Periodically (0.5, 2, 4, 6, 8, 10, 12,
14, 16, 18, 20, 22, 24, 28, 32, 36, 40, 44, and 48 h), 0.5 mL
of release medium was removed replaced with new buffer.
DOX concentration and percentage of released DOX dur-
ing a period of time were detected at 485 nm.
Cell Lines and Culture
The human breast cancer MCF-7 cell line was pur-
chased from American Type Culture Collection (Manas-
sas, VA). The cell line was authenticated twice by
morphologic and isoenzyme analyses during the study
period. Cell lines were routinely checked for contamination
by mycoplasma using Hoechst staining and consistently
found to be negative. The cells were maintained at 37 °C in
5% CO2 in DMEM supplemented with 10% FBS, 100 U/
mL penicillin, and 100 μg/mL streptomycin (Invitrogen,
Carlsbad, CA). Medium was changed every other day.
Cytotoxicity Assays
For cytotoxicity assays, the MCF-7 cells were seeded into
96-well plates (0.1 ml/well, 5 × 103 cells/well) and incu-
bated overnight until the cells reached 80% confluence.
The cells were treated with fresh medium containing a
known concentration of drug formulations ranging from
0.1 to 20 μg/mL in each well in triplicates, and the plates
were incubated for 48 h. Another experiment, MCF-7
cells were co-treated with micelles at the concentration
equivalent to 2 μg/mL DOX and 10 mM 3-MA or
60 μM CQ. The MCF-7 cells were incubated with those
regents for 24 h.
Before harvest, the cytotoxicity was evaluated by add-
ing 10 μL of CCK-8 solution to each well of the plate.
After incubation for 1 h, the absorption of the samples
in each well was measured using a BIO-TEK ELx800
Universal Microplate Reader (Bio-Tek, VT, USA) at
wavelengths of 450 and 630 nm. The cell survival rate
was calculated with the following formula: [(AE −AB)/
(AC − AB)] × 100%, where AE, AC, and AB represent the
absorbance of the experimental cells [23], control cells,
and background, respectively.
The IC50 of the drugs was calculated by the CompuSyn
software (Chou and Martin, 2005, Compusyn, Inc., USA).
Cellular Uptake Analyses
The cellular uptake behaviors of the nanoparticle in
MCF-7 were analyzed using both flow cytometry (BD
biosciences, CA) and confocal laser scanning microscopy
(CLSM) (Carl Zeiss Meditec AG, Jena, Germany). For
flow cytometry analyses, cells were seeded in 12-well
plates at a density of 2 × 105 cells/mL and incubated
overnight. Then, the cells were treated with AX-DOX,
DOX at a concentration of 2 μg/mL, and the culturemedium was used as a blank control. After incubation
for 8 h, the cells were washed with PBS. The cellular up-
take of drugs was analyzed using a flow cytometer and
FlowJo analysis software. For each sample, at least 2 ×
104 cells were analyzed.
For the CLSM studies, the MCF-7 cells were precul-
tured in confocal laser scanning dishes at a density of
2 × 105 cells per well overnight. The cells were treated
with AX-DOX, DOX at a concentration of 2 μg/mL, and
co-incubated with 10 mM 3-MA or 60 μM CQ for 8 h,
respectively. The cells were then washed with PBS. Un-
treated cells were used as control. The cellular uptake
was observed with a CLSM. Digital monochromatic im-
ages were acquired using ZEN Light Edition Software.
Apoptotic Cells Evaluated by Flow Cytometry
The antitumor activity of different drug formulations
was analyzed as described below. Briefly, MCF-7 cells
were seeded into 24-well plates (5 × 104 cells/well) and
incubated overnight. After the cells reached 80% conflu-
ence, they were treated with drug at 37 °C with 5% CO2
for 48 h. The cells were trypsinized, collected, washed,
and finally suspended in one-time binding buffer, followed
by staining with an Annexin-V antibody labeled with
Alexa Fluor-488 for 15 min at RT in the dark. Then, the
apoptotic cells were analyzed by flow cytometry [24]. For
each sample, at least 1 × 104 cells were analyzed.
In Vivo Anticancer Study
Female Balb/c nude mice (4 weeks, ~20 g) were ob-
tained from the Shanghai Experimental Animal Center
of Chinese Academic of Sciences (Shanghai, China) and
kept under specific pathogen-free (SPF) conditions. They
were allowed to acclimate 1 week in the animal facility
to reduce stress after arrival, and all efforts were made
to minimize animal suffering. A subcutaneous MCF-7
tumor xenograft mouse model was established by sub-
cutaneously implanting 2 × 107 MCF-7 cells into the
right back of each 5-week-old female mouse. Two weeks
after inoculation, mice with palpable tumors about
50 mm3 were randomized into three groups (5 mice per
group). The three groups of tumor-bearing mice were
injected with (1) PBS (control), (2) AX-DOX (5 mg/kg
BW), (3) saturated aqueous solution of hydrophobic
DOX (5 mg/kg BW) every 3 days for a total of three
treatments. A total of 100 μL of PBS was used as the
carrier for all drug formulations. Tumor volumes were
measured by an external caliper every 3 days and were
then calculated by the modified ellipsoidal formula:
Tumor volume = (length × width2)/2. For the analysis of
systemic toxicity of treatment, the body weight change
was monitored at the same time. The mice were eutha-
nized on day 33 after the drug injection. All animals
were treated in accordance with guidelines of the
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Statistical Analysis
All data are reported as mean ± standard deviation (SD)
from at least three independent runs. Statistical analysis
of significance was calculated using Student’s t test. p <
0.05 is considered as statistically significant.
Results and Discussion
Synthesis and Characterization of Micelles and Drug
Encapsulation
The synthesis of AX-drug conjugates was shown in Fig. 1.
Shortly, the DOX·HCL was dehydrochlorinated by the
TEA solution firstly. Then, the hydrophobic DOX was
linked to the AX by the hydrogen bond. The well-
defined core shell micelles were self-assembled from the
amphiphilic AX-DOX chains by dialysis method. DOX
was encapsulated inside of micelles through hydrogen
bond and hydrophobic interaction. Noted here, the
hydrogen bond is cleavable at low pH.Fig. 1 The scheme illustrated the synthesis and assembly process of micellAverage hydrodynamic diameters, measured by dy-
namic light scattering (DLS), of blank nanocarrier and
DOX-loaded micelles were all at the range from 20 to
1000 nm. Noted, we found the hydrodynamic diameter
and size distribution of micelles after packaged DOX be-
came smaller. These results suggested that the DOX-
nanocarrier interactions through hydrogen bond and
hydrophobic interaction can prevent the micelles from
forming aggregates in aqueous solution and distributed
more uniform [19] (Fig. 2a). Morphologically, scanning
electron microscopy (SEM) images indicate that both
the AX-DOX micelles have a narrow size distribution
and AX have a anomalous formation (Fig. 2b). It is
worth noting that the particle size of AX-DOX is more
uniform than AX because the formation of hydrogen
bond and hydrophobic interaction changes the original
configuration of AX, prevents the aggregation, and pro-
motes more uniform distribution. The EE and DLC of
AX-DOX micelles are 43.12 ± 2.1% and 48.61 ± 1.3%
(Fig. 2c). In addition, control experiments were per-
formed at RT using 1 mg of DOX placed inside a dialysises with well-defined structure
Fig. 2 Characterization of micelles. a DLS testing of blank nanocarrier and DOX-loaded micelles in aqueous solution. b SEM images of AX and
AX-DOX micelles showing their homogeneous size distribution. c The EE and DLC of DOX micelles. d The in vitro cumulative DOX released from
the AX-DOX micelles in different pH media at RT over a time period of 48 h. Data are expressed as mean ± SD (n = 3)
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DOX-loaded nanopatricles was investigated in three dif-
ferent buffer solutions (PBS/pH 7.4; PBS/pH 6.5; PBS/
pH 4.5) individually. The cumulative release ratio of AX-
DOX micelles was calculated to be approximately 12.3,
23.5, and 24.5% at pH 7.4, pH 6.5, and pH 4.5 within
48 h, respectively (Fig. 2d). Obviously, the micelles had a
high release ratio in the acidic environment while a low
DOX release in the neutral pH condition. That is, the
release ratio increases with the decrease of the media
pH value. The AX-DOX micelles are stability in neutral
solution, limiting the release of DOX. However, the mi-
celles can dissolve into the acidic media, which promotes
hydrogen bonds cleavage [23], therefore the micelles are
disintegrated and promote the release of DOX.
In Vitro Cytotoxicity of the AX-DOX Micelles
Different concentrations (0.1, 0.5, 1, 2, 4, 8, 12, 20 μg/
mL) of the AX, DOX, AX-DOX, and the blend AX with
DOX were prepared for evaluating biocompatibility of
the AX and the cytotoxicity of AX-DOX against MCF-7
cells. These assays can help to distinguish whether blank
nanocarrier is biocompatible and to evaluate the AX-DOX toxicity to tumor cells. Interestingly, it was ob-
served that the cells treated with AX for 48 h were
growth better (Fig. 3a) because of the fair nutritive value
of AX. So, our nanocarrier has good biocompatibility
and will not perform functions in loaded drugs’ chemo-
therapy. The effects of AX-DOX on proliferation inhib-
ition of MCF-7 cells were also evaluated using CCK-8
assay after 48 h of treatment. As shown in Fig. 3a, AX-
DOX micelles were much more effective at suppressing
MCF-7 cells proliferation than other groups, especially
when the concentration was lower than 4 μg/mL. As
shown in Fig. 3b, the IC50 value of AX-DOX, DOX, and
AX +DOX was 1.207, 4.633, and 6.776 μg/mL, respect-
ively. Interestingly, the IC50 of AX +DOX was higher
than other groups because of the fair nutritive value of
AX. The IC50 in MCF-7 cells shown AX-DOX was 3.84-
fold effective than DOX, indicating that the AX-DOX
have much better antitumor therapeutic effect. The en-
hanced cytotoxicity of micelles over hydrophobic DOX
is attributed to their enhanced cellular uptake, via
slightly acidic environments, in the MCF-7 cells. The
difference observed in cytotoxicity result from the differ-
ent mechanism of cellular uptake for free drug versus
Fig. 4 In vitro evaluation of the cellular uptake of micelles. a In vitro
cellular uptake tested by flow cytometry for different DOX formulations.
b CLSM images of MCF-7 cells. The cells were treated with AX-DOX,
DOX at a concentration of 2 μg/mL and co-incubated with 10 mM 3-
MA or 60 μM CQ for 8 h at 37 °C, respectively. c The in vitro cytotoxicity
of the different DOX formulations under 10 mM 3-MA or 60 μM CQ to
MCF-7 tumor cells. Data are expressed as mean ± SD (n = 3). *p < 0.05;
**p < 0.01; ***p < 0.001; NS not significant
Fig. 3 In vitro evaluation of the anti-proliferative efficacy of micelles. a The cytotoxic profile of blank nanocarriers, AX-DOX micelles, the DOX, and
the blend AX with DOX at different concentrations after 48 h incubation with MCF-7. b IC50 value of the different DOX formulations. c The cell
apoptosis induced by AX, DOX, and AX-DOX in MCF-7 cells; non-treated cells used as control. All values are presented as a mean SD (n = 3)
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curs through a passive diffusion mechanism, while mi-
celles are taken up by endocytosis, which overcome the
low-efficiency problem. Therefore, these results demon-
strate that micelles optimally inhibited MCF-7 cells pro-
liferation in vitro.
The in vitro apoptosis-inducing capacity of AX-DOX
was also evaluated via flow cytometry using 1 × 104
MCF-7 cells for each sample. After staining, apoptotic
cells were characterized based on Annexin V+ subsets.
As shown in Fig. 3c, in comparison with the control
group, after treatment with AX, DOX, and AX-DOX at
concentration of 2 μg/mL for 48 h, the proportions of
apoptotic cells were 2.16, 3.57, 9.16, and 37.64%, respect-
ively. The increasing proportion of apoptotic cells in-
duced by AX-DOX fully demonstrates that AX-DOX has
a potent capacity in cancer therapy by proliferation in-
hibition and apoptosis.
In Vitro Synergistic Cytotoxicity Induced by AX-DOX
Based on the fluorescent intensity of the DOX, the cellu-
lar uptake of micelles was detected by flow cytometry
and CLSM. The image shows that the cellular uptake of
AX-DOX was higher than DOX (Fig. 4a, b). The CLSM
images indicated that the release and distribution of mi-
celles were different in diverse pH environment (Fig. 4b).
3-MA can suppress the autophagosomes formation,
while CQ can block endosomes and autophagosomes fu-
sion with lysosomes, therefore lead the significant accu-
mulation of the autophagosomes [25]. It is well known
that the pH value of the normal cells or tissues is ~7.3,
while it is weakly acidic in tumor tissues (pH 6.2–6.9),
especially in some organelles, such as endosomes
(~pH 6.0), autophagosomes (~pH 5.0), and lysosomes
(pH 4.5–5.0), the acidity is much higher [26]. Inhibition
of autophagy can rescue the micelles from endosome
and lysosome, and thus sustains the micelles existence
in different organelles to evaluate the release of the drug
under different pH. Our previous studies demonstrated
that the size of micelles is small and the nanocarrier ishydrophilic with pH-sensitive to increase the cellular up-
take of the micelles in MCF-7 cells. Moreover, the re-
sults (Fig. 4c) of cytotoxicity of the different DOX
formulations under 3-MA or CQ further validate that
the release ratio of drug increased with the decrease of
the pH value. Thus, the cytotoxicity of AX-DOX was
promoted by both the intratumor accumulation and the
intracellular low pH.
Fig. 5 In vivo evaluation of the antitumor efficacy of micelles. a Tumor growth curves for the different DOX formulations with a dosage of 5 mg/
kg and a total of three treatments. All values are presented as a mean SD (n = 5); *p < 0.05; **p < 0.01; ***p < 0.001; NS not significant. b Images of
the tumors collected after sacrificing the mice on day 33. When tumors were established and reached ~50 mm3, mice were treated with the
various drug formulations. The tumor volume (V) was calculated as: V ¼ LW
2ð Þ
2 , where L is long diameter and W is short diameter of tumor
determined using a caliper. c Change in the body weight of animals as a function of time
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Our micelles were therefore applied to be administrated
into Balb/c nude mice bearing MCF-7 cells to evaluate
antitumor therapeutic effect. The change of tumor vol-
ume shows in Fig. 5a, b. All of the treatment groups ex-
hibited inhibition of tumor growth as compared to the
PBS control group. Overall, the AX-DOX micelles were
the most effective at inhibiting tumor growth compared
to the control, measured 33 days after the last injection.
As expected, AX-DOX micelles induce much betterFig. 6 Scheme illustrated the cellular level mechanism of the AX-DOX formantitumor efficacy than free DOX at the same dosage,
which is consistent with the in vitro CCK-8 assay find-
ings. This observation can be largely contributed to the
fact that the AX-DOX can significantly enhance the
tumor cellular accumulation. In other words, the cellular
uptake of the micelles in MCF-7 cells is dramatically en-
hanced compared to that of free DOX, which is partly
attributed to the enhanced permeability and retention
(EPR). In addition, as the micelles enter into cells, it will
encounter a low-pH environment. This is because theulation
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especially in some organelles, such as endosomes and ly-
sosomes, the acidity is much higher (pH 4.5–6.0). The
acidic environment promotes the hydrogen bond break-
ing, which results in the degradation of micelles and suc-
cessful intracellular release drug. Furthermore, during
the whole treatment process, there were not any notice-
able changes in body weight (Fig. 5c), indicating that the
AX-DOX system is safe.
Consequently, the intratumor accumulation of AX-
DOX is attributed to the well-known EPR. Meanwhile, the
AX-DOX with pH-cleavable bond can promote the release
of the drug in tumor accompanied with obvious apoptosis
(Fig. 3c). As schemed in Fig. 6, the therapeutic effects of
AX-DOX are attributed to both the proliferation inhib-
ition and apoptosis, which was further synergistically pro-
moted by the EPR and intracellular pH-triggered drug
release. All the results indicate that such AX-DOX micel-
lular formulation held high potential in cancer therapy.
Conclusions
In this work, by employing AX as a natural nanocarrier
encapsulating DOX, the AX-DOX micelles with pH-
sensitivity, and high biocompatibility were synthesized
and characterized for MCF-7 breast cancer synergistic
therapy. The DOX release from AX-DOX micelles is
dependent upon the cleavage of hydrogen bonds and
drug-nanocarrier interactions, which are influenced by
the environmental pH. The in vitro cytotoxicity against
MCF-7 cells showed that such AX-DOX micelles dra-
matically enhanced the cellular uptake of DOX, owing
to the synergistic effects of proliferation inhibition and
apoptosis. Consequently, the in vivo tumor inhibition by
this AX-DOX was dramatically promoted, indicating
that the AX-DOX exhibited a significantly higher tumor
accumulation and better antitumor efficacy than DOX.
These in vitro/vivo results indicated that the improved
therapeutic effect of AX-DOX over DOX in MCF-7 cells
is attributed to the good pH-triggered drug release cap-
ability, excellent biocompatibility, and effective antitu-
mor activity of the AX-DOX micelles.
Abbreviations
3-MA: 3-Methyladenine; AX: Arabinoxylan; CCK-8: Cell counting kit-8;
CLSM: Confocal laser scanning microscope; CQ: Chloroquine; DLC: Drug
loading capacity; DLS: Dynamic light scattering; DMAC: N,N-
dimethylacetamide; DMEM: Dulbecco’s modified Eagle’s medium;
DOX: Doxorubicin; DOX HCl: Doxorubicin hydrochloride; EE: Encapsulation
efficiency; EPR: Enhanced permeability and retention; FBS: Fetal bovine
serum; MCF-7: Breast cancer cells; MWCO: Molecular weight cutoff; RT: Room
temperature; SD: Standard deviation; SEM: Scanning electron microscopy;
SPF: Specific pathogen-free; TEA: Triethanolamine
Funding
This work was partly supported by Taishan Scholar Program and Shandong
Provincial Natural Science Foundation, China (ZR2013HZ002 and
2014GSF118121). This work was also financially supported by the National
Natural Science Foundation of China including the projects (31470964,81171450, 81302363) and by Ministry of Science and Technology of China
(2012AA02A304).
Authors’ Contributions
JW, YLL, and XD were actively involved in the all the physical and biological
experiments. WL and JH have originally designed the research project and
written the entire manuscript. All authors read and approved the final manuscript.
Competing Interests
The authors declare that they have no competing interests.
Ethics Approval and Consent to Participate
The authors state that they have obtained appropriate institutional review
board approval or have followed the principles outlined in the Declaration of
Helsinki for all human or animal experimental investigations. In addition, for
investigations involving human subjects, informed consent has been
obtained from the participants involved.
Author details
1College of Pharmacy & Institute of Biopharmaceutical Research, Liaocheng
University, 1 Hunan Road, Liaocheng, Shandong 252000, People’s Republic of
China. 2International Joint Cancer Institute, The Second Military Medical
University, 800 Xiangyin Road, Shanghai 200433, People’s Republic of China.
3School of Chemical and Material Engineering, Jiangnan University, 1800 Lihu
Avenue, Wuxi 214122, People’s Republic of China.
Received: 14 December 2016 Accepted: 7 January 2017
References
1. Kovalchuk O, Filkowski J, Meservy J, Iinytskyy Y, Tryndyak VP, Chekhun VF et al
(2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer
cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7(7):2152–9
2. Cao N, Feng SS (2008) Doxorubicin conjugated to D-alpha-tocopheryl
polyethylene glycol 1000 succinate (TPGS): Conjugation chemistry,
characterization, in vitro and in vivo evaluation. Biomaterials 29(28):3856–65
3. Maeng JH, Lee DH, Jung KH, Bae YH, Park IS, Jeong S et al (2010)
Multifunctional doxorubicin loaded superparamagnetic iron oxide
nanoparticles for chemotherapy and magnetic resonance imaging in liver
cancer. Biomaterials 31(18):4995–5006
4. Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM et al (2009)
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin.
Nanomedicine 5(4):410–8
5. Soares PIP, Dias SJR, Novo CMM, Ferreira IMM, Borges JP (2012) Doxorubicin
vs. ladirubicin: methods for improving osteosarcoma treatment. Mini Rev
Med Chem 12(12):1239–49
6. Li W, Feng SS, Guo YJ (2012) Block copolymer micelles for nanomedicine.
Nanomedicine 7(2):169–72
7. Li W, Zhao H, Qian WZ, Li HF, Zhang L, Ye ZW et al (2012) Chemotherapy
for gastric cancer by finely tailoring anti-Her2 anchored dual targeting
immunomicelles. Biomaterials 33(21):5349–62
8. Feng ZL, Zhao G, Yu L, Gough D, Howell SB (2010) Preclinical efficacy
studies of a novel nanoparticle-based formulation of paclitaxel that out-
performs Abraxane. Cancer Chemother Pharmacol 65(5):923–30
9. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the
clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4):505–15
10. Li W, Zhao MX, Ke CH, Zhang G, Zhang L, Li HF et al (2013) Nano
polymeric carrier fabrication technologies for advanced antitumor
therapy. Biomed Res Int 2013:9
11. Wu J, Lu YH, Lee A, Pan XG, Yang XJ, Zhao XB et al (2007) Reversal of
multidrug resistance by transferrin-conjugated liposomes co-encapsulating
doxorubicin and verapamil. J Pharm Pharm Sci 10(3):350–7
12. Li W, Guo QC, Zhao H, Zhang L, Li JF, Gao J et al (2012) Novel dual-control
poly(N-isopropylacrylamide-co-chlorophyllin) nanogels for improving drug
release. Nanomedicine 7(3):383–92
13. Lee ES, Gao ZG, Kim D, Park K, Kwon IC, Bae YH (2008) Super pH-sensitive
multifunctional polymeric micelle for tumor pH(e) specific TAT exposure
and multidrug resistance. J Control Release 129(3):228–36
14. Unsoy G, Khodadust R, Yalcin S, Mutlu P, Gunduz U (2014) Synthesis of
doxorubicin loaded magnetic chitosan nanoparticles for pH responsive
targeted drug delivery. Eur J Pharm Sci 62:243–50
Wang et al. Nanoscale Research Letters  (2017) 12:73 Page 9 of 915. Grootaert C, Delcour JA, Courtin CM, Broekaert WF, Verstraete W, Van de Wiele
T (2007) Microbial metabolism and prebiotic potency of arabinoxylan
oligosaccharides in the human intestine. Trends Food Sci Technol 18(2):64–71
16. Mai HB, Tran VR, Nguyen TT, Le HS, Trinh TD, Le VT et al (2010)
Arabinoxylan rice bran (MGN-3) enhances the effects of interventional
therapies for the treatment of hepatocellular carcinoma: a three-year
randomized clinical trial. Anticancer Res 30(12):5145–51
17. Lee CJ, Nah CS, Teng CS, Jun WW, Saravanan M (2015) Spray dried calcium
gelled arabinoxylan microspheres: a novel carrier for extended drug
delivery. Chem Papers 69(10):1325–30
18. El-Din NKB, Ali DA, El-Dein MA, Ghoneum M (2016) Enhancing the
apoptotic effect of a low dose of paclitaxel on tumor cells in mice by
arabinoxylan rice bran (MGN-3/Biobran). Nutr Cancer Int J 68(6):1010–20
19. Nishiyama N, Kataoka K (2003) Polymeric micelle drug carrier systems:
PEG-PAsp(Dox) and second generation of micellar drugs. Adv Exp Med
Biol 519:155–77
20. Kim S, Shi YZ, Kim JY, Park K, Cheng JX (2010) Overcoming the barriers in
micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell
interaction. Expert Opin Drug Deliv 7(1):49–62
21. Lee ES, Gao ZG, Bae YH (2008) Recent progress in tumor pH targeting
nanotechnology. Journal of Controlled Release 132(3):164–70
22. Kievit FM, Wang FY, Fang C, Mok H, Wang K, Silber JR et al (2011)
Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance
in cancer in vitro. J Control Release 152(1):76–83
23. Scheeren LE, Nogueira DR, Macedo LB, Vinardell MP, Mitjans M, Infante MR
et al (2016) PEGylated and poloxamer-modified chitosan nanoparticles
incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
Colloids Surf B Biointerfaces 138:117–27
24. Zhang FL, Zhu XD, Gong J, Sun Y, Chen D, Wang J et al (2016) Lysosome-
mitochondria-mediated apoptosis specifically evoked in cancer cells
induced by gold nanorods. Nanomedicine 11(15):1993–2006
25. Zhang XD, Dong YC, Zeng XW, Liang X, Li XM, Tao W et al (2014) The effect
of autophagy inhibitors on drug delivery using biodegradable polymer
nanoparticles in cancer treatment. Biomaterials 35(6):1932–43
26. Tannock IF, Rotin D (1989) Acid pH in tumors and its potential for
therapeutic exploitation. Cancer Res 49(16):4373–84Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
